About Us
Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

73°
- Woonsocket, RI (02895)
  
  Today
  
  Mainly cloudy. Areas of dense fog. Low around 55F. Winds E at 5 to 10 mph..
  
  Tonight
  
  Mainly cloudy. Areas of dense fog. Low around 55F. Winds E at 5 to 10 mph.
  
  Updated: October 22, 2020 @ 4:56 pm
- Full Forecast

Home
News
Sports
Opinion
Lifestyle
- Local Entertainment
Multimedia
- Photos
- Videos
Features
Classifieds
- Place Ad
Obituaries

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Marinus Pharma CS (NQ: MRNS )

12.67 USD +0.07 (+0.56%)

Official Closing Price Updated: 5:43 PM EST, Jan 19, 2021 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press releases about Marinus Pharma CS

< Previous 1 2 3 4 5 6 Next >

Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting

November 27, 2019

Company to host KOL Breakfast and live webcast at 7am ET on Monday, Dec 9

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 08, 2019

From GlobeNewswire News Releases

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

November 06, 2019

From GlobeNewswire News Releases

Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

October 29, 2019

From GlobeNewswire News Releases

Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

October 17, 2019

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

September 27, 2019

From GlobeNewswire News Releases

Thinking about buying stock in Beyond Meat, Canopy Growth, Marinus Pharmaceuticals, Rite Aid, or 22nd Century Group?

September 26, 2019

InvestorsObserver issues critical PriceWatch Alerts for BYND, CGC, MRNS, RAD, and XXII.

From PR Newswire

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

September 26, 2019

From GlobeNewswire News Releases

NIRI Philadelphia Elects New Board Members

August 29, 2019

National Investor Relations Institute Philadelphia Chapter Announces New Board of Directors & September Meeting on "The Board's Perspective on IR"

From Business Wire News Releases

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 23, 2019

From GlobeNewswire News Releases

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

August 08, 2019

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression

July 23, 2019

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other...

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

June 19, 2019

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric...

From GlobeNewswire News Releases

Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences

June 03, 2019

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Dr....

From GlobeNewswire News Releases

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results

May 01, 2019

Enrollment complete in Magnolia and Amaryllis studies

From GlobeNewswire News Releases

New Research Coverage Highlights Quanta Services, Kansas City Southern, Oceaneering International, Marinus Pharmaceuticals, Allegion, and Craft Brew Alliance — Consolidated Revenues, Company Growth, a

April 03, 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quanta Services, Inc....

From GlobeNewswire News Releases

Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results

March 11, 2019

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business...

From GlobeNewswire News Releases

Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results

March 10, 2019

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business...

From GlobeNewswire News Releases

Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy

March 05, 2019

Study designed to evaluate a clinically relevant predictive biomarker that aims to identify high responding patients

From GlobeNewswire News Releases

Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference

March 04, 2019

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...

From GlobeNewswire News Releases

Marinus Announces Leadership Transition

February 26, 2019

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric...

From GlobeNewswire News Releases

Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference

February 19, 2019

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 05, 2019

From GlobeNewswire News Releases

New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019

January 29, 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc....

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

January 25, 2019

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

December 12, 2018

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of...

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Public Offering of Common Stock

December 11, 2018

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering....

From GlobeNewswire News Releases

Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression

December 09, 2018

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other...

From GlobeNewswire News Releases

Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients

December 03, 2018

From GlobeNewswire News Releases

Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES

November 18, 2018

From GlobeNewswire News Releases

< Previous 1 2 3 4 5 6 Next >

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Sections

Home
News
Sports
Opinion
Multimedia
Calendar
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Personnel
Subscriber Services
Online Forms
Rack Locations

Facebook
Twitter

Contact

woonsocketcall.com
Address: 75 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: info@woonsocketcall.com

Woonsocket, RI (02895)

Today

Tonight

Marinus Pharma CS (NQ: MRNS )

Press releases about Marinus Pharma CS

Sections

Services

Follow Us

Contact